

1FW
CASE LA0085 NP**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Burton Rodney
Type or print name


Signature

September 8, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

CHENG ET AL.

Examiner: Charanjit Aulakh

APPLICATION NO: 10/616,283

FILED: JULY 8, 2003

FOR: SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS
ANTIDIABETIC AND ANTI OBESITY AGENTS AND METHOD

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 CFR §1.97(d)

Sir:


Consideration of the Information Disclosure Statement submitted concurrently herewith is requested. Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee for filing this petition.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

09/13/2004 CNGUYEN 00000056 193880 10616283
01 FC:1806 180.00 DA

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336
Date: September 8, 2004

Respectfully submitted,


Burton Rodney
Attorney for Applicants
Reg. No. 22,076




23914

PATENT TRADEMARK OFFICE

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Burton Rodney", is written over a horizontal line.

Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date: September 8, 2004

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
LA0085 NP
APPLICATION NO.
10/616,283
APPLICANT
CHENG ET AL.
FILING DATE
JULY 8, 2003Group
1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,414,002	7/2/02	Cheng et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 97/31907 A1	9/4/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 99/46232 A1	9/16/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cobb et al., "N-(2-benzoylphenyl)-L-tyrosine PPAR gamma agonist 3. Structure-activity relationship and optimization of the N-aryl substituent". Journal of Medicinal Chemistry, 1998, Vol. 41, No. 25, pages 5055-5069.
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.